Abeona Therapeutics sees strong commercial momentum for its RDEB therapy ZEVASKYN, reporting 31% revenue growth and broad market access despite ongoing administrative hurdles in patient onboarding.
Abeona reported $11.4 million in quarterly net product revenue, up 31% sequentially, with 12 commercial patients treated and broad coverage, indicating strong launch momentum.
Abeona Therapeutics reported $11.4 million in quarterly net product revenue, marking a 31% sequential increase for its gene therapy, ZEVASKYN. The company has successfully treated 12 commercial patients across seven qualified centers, supported by broad insurance coverage and a $146 million cash position to fuel ongoing commercial and pipeline development.
Abeona is focused on the commercial launch of ZEVASKYN, an autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB).
While insurance coverage is broad, administrative hurdles such as prior authorizations and single-case agreements between treatment centers and payers continue to slow the pace of patient treatment.